The main sites of bleeding with rivaroxaban are the gastrointestinal tract, genitourinary tract, respiratory tract, cranial region, and conjunctiva. Rivaroxaban is a medicine that fights blood clot formation. It is used to prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery. Its spinal/epidural hematoma, and bleeding risk cannot be ignored. Taking rivaroxaban bleeding site is mainly seen in: ① gastrointestinal tract: seen in gum bleeding, rectal bleeding, esophageal bleeding, manifested as vomiting blood, black stools and so on. ② Genitourinary tract: seen in hematuria, menorrhagia, etc.. ③Respiratory tract: seen in nosebleed, tracheal hemorrhage, lung bruise, etc., manifested as hemoptysis. ④ Cranium: mainly seen in basal ganglia hemorrhage. ⑤ Conjunctiva: seen as conjunctival hemorrhage. In addition to the adverse effects of rivaroxaban, which have a tendency to bleed, the adverse effects of rivaroxaban include an increased risk of stroke after early discontinuation of the drug in patients with nonvalvular atrial fibrillation, and spinal/epidural hematomas. Rivaroxaban is contraindicated in patients with hypersensitivity to rivaroxaban, patients with significant active bleeding, coagulation abnormalities, and hepatic disease at risk of bleeding, and pregnant and lactating women. Rivaroxaban should be used under professional medical supervision.